Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anne Lenz

Pediatric Endocrinology St Petersburg, FL Medical Doctor

NPI 1093908048 CMS profile 276978

501 6Th Ave S, Box 6900, St Petersburg, FL 33701

Open in the dashboard

General payments

$5,250

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anne Lenz of St Petersburg, FL is reported in the CMS Open Payments database as having received $5,250 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,392 57
2024 General $1,273 58
2023 General $1,141 49
2022 General $750 43
2021 General $577 38
2020 General $86 5
2019 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anne Lenz
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Anne Lenz were reported at $1,392. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Anne Lenz Pediatric Endocrinology median Middle half National median
2019 $32 $196 $68–$845 $163
2020 $86 $124 $37–$722 $114
2021 $577 $134 $35–$691 $132
2022 $750 $177 $47–$726 $149
2023 $1,141 $236 $75–$887 $160
2024 $1,273 $259 $91–$979 $164
2025 $1,392 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $558 35 payments
  2. Ascendis Pharma, Inc. $548 25 payments
  3. Dexcom, Inc. $433 22 payments
  4. Sanofi-Aventis U.S. LLC $373 16 payments
  5. Novo Nordisk Inc $358 19 payments
  6. Neurocrine Biosciences, Inc. $297 12 payments
  7. Eton Pharmaceuticals, Inc. $287 3 payments
  8. Pfizer Inc. $233 12 payments
  9. Insulet Corporation $226 11 payments
  10. Xeris Pharmaceuticals, Inc. $217 12 payments
  11. Other $1,721 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,224 247 payments
  2. Education $26 5 payments
Products named General payments · program years 2019–2025
  1. SKYTROFA $548 25 payments
  2. LUPRON DEPOT $471 29 payments
  3. TZIELD $373 16 payments
  4. Dexcom G6 Transmitter $346 17 payments
  5. Sogroya $289 16 payments
  6. Alkindi $287 3 payments
  7. CRENESSITY $241 10 payments
  8. Omnipod $226 11 payments
  9. GENOTROPIN $216 11 payments
  10. FENSOLVI $215 15 payments
  11. Other $2,625 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record